Published on: 18 February 2021
This statement is a FSRH CEU response to a public consultation conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding licensing of two brands of desogestrel 75mcg progestogen-only pill (POP) as Pharmacy Medicines (P). The products are Hana® (Laboratoire HRA Pharma) and Lovima® (Maxwellia Ltd).
Your download should start automatically. If not download directly.